Diuretic linked to lower dementia odds in UK Biobank
Bendroflumethiazide was the only drug linked to lower dementia odds in UK Biobank, with an odds ratio of 0.977; one means no difference.

Our read
Populations- Studied:
- Cohort study of 166,381 cardiovascular drug users (Dose-response)
- What changed:
- Dementia odds were lower among bendroflumethiazide users (odds ratio 0.977)
- The catch:
- Prescription counts may not reflect how much bendroflumethiazide people actually took
Editor of record: Boris Djordjevic · AgingResearch.News
UK Biobank participants—502,359 people, including 166,381 cardiovascular drug users—were included in a drug-wide association study searching for links between cardiovascular medicines and dementia. Bendroflumethiazide was the only drug linked to lower odds of developing dementia. It belongs to the thiazide diuretics, medicines that help the body remove salt and water.
An independent analysis of NHS clinical records for 267,360 people linked each ten additional bendroflumethiazide prescriptions to a 4.2% lower risk of developing dementia. A Mendelian randomization analysis used genetic variants as proxies for thiazide action. These variants were associated with less vascular cognitive impairment—problems with thinking related to blood vessel damage—but not Alzheimer’s dementia. The authors identified thiazide diuretics as promising candidates for dementia prevention trials.
Why it matters
Preventing dementia is an important goal for aging populations. Repurposing established medicines offers a potentially faster, less costly route to testing prevention strategies.
Caveats
People receiving more or fewer prescriptions may have differed in other ways related to dementia risk. The UK Biobank drug search focused on cardiovascular drug users, so it does not establish benefits for people without that treatment need.
The paper
Cerebral Circulation - Cognition and Behavior, Nov 2026, CC BY-NC-ND


Comments
Be the first to comment.